Across TCGA pan-cancer cohorts, ZNF517 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF517 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF517 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF517 expression acts as an unfavorable survival marker.
LUAD, LIHC, and KIRP are the cancer types where ZNF517 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.